Corporate Presentation

May 17, 2023

CRB-601 Unlocking the Potential of αvβ8 Blockade – Antitumor Activity and Immune Remodeling

May 3, 2023

Partnership Project (CRB-913): an oral cannabinoid type-1 inverse agonist for obesity